Mirococept

Phase III Active

A complement inhibitor potentially for the treatment of reperfusion injury.

Research Code APT-070; APT-070C

CAS No.

LD22-4

Phase I Pending

An angiogenesis inhibitor potentially for the treatment of age-related macular degeneration (AMD).

Research Code LD22-4

CAS No.

MK-8719

Phase I Active

A drug potentially for the treatment of progressive supranuclear palsy.

Research Code MK-8719

CAS No.

HIV vaccine (Institute of Human Virology/Profectus Biosciences)

Phase I Active

An antiviral immune modulating (AIM) therapeutic potentially for the treatment of HIV infection.

Research Code IHV 001; IHV-01

CAS No.

Anti-LeY-CAR

Phase I Pending

A CAR T cell therapy potentially for the treatment of multiple myeloma, acute myeloid leukaemia and myelodysplastic syndrome.

Research Code Anti-LeY-CAR

CAS No.

Ensituximab

Phase II Active

A tumour-associated antigen (TAA) targeted antibody potentially for the treatment of colorectal cancer and pancreatic cancer.

Research Code NEO-101; NEO-102; NPC-1-C

CAS No.

Racotumomab

(Vaxira^®) Approved

An anti-idiotype monoclonal antibody potentially for the treatment of non small cell lung cancer (NSCLC).

Research Code 1E10

CAS No. 946832-34-4

IMM-124E

Phase II Active

A hyperimmune bovine colostrum powder potentially for the treatment of alcoholic hepatitis, non-alcoholic steatohepatitis and autistic disorder.

Research Code IMM-124E; IMM122-I

CAS No.

SGM-101

Phase II Active

A CEA targeted antibody conjugated to a near-infrared fluorochrome potentially for the detection of breast cancer, gastric cancer, pancreatic cancer and rectal cancer.

Research Code SGM-101

CAS No.

MDX-1303

(Valortim^®) Phase I Active

An anthrax toxin inhibitor potentially for the treatment of anthrax.

Research Code MDX-1303; MAb-1303

CAS No.

Alcaftadine

(Lastacaft^®) Approved

A histamine H1 receptor (HRH1) inhibitor used to prevent eye irritation.

Research Code R-89674

CAS No. 147084-10-4(Alcaftadine)

AFM-11

Phase I Active

A CD19 and CD3 targeted bispecific TandAb potentially for the treatment of non-Hodgkin's lymphoma.

Research Code AFM-11

CAS No.

AFM-13

Phase II Active

A bispecific antibody targeting FcγRIIIa (CD16a) and CD30 receptor potentially for the treatment of Hodgkin lymphoma.

Research Code AFM-13

CAS No.

Anti-CD34 mab-sirolimus (OrbusNeich)

Approved

An anti-CD34 antibody-coated drug-eluting stent used for prevention of coronary artery restenosis.

Research Code

CAS No. 53123-88-9

Oglufanide disodium

(Thymogen^®) Phase III Discontinued

An angiogenesis inhibitor potentially for the treatment of Kaposi's sarcoma.

Research Code IM-862

CAS No. 237068-57-4(Oglufanide disodium)  38101-59-6(Oglufanide)

Etanercept biosimilar (Coherus Biosciences)

Phase III Active

A tumour necrosis factor (TNF) inhibitor potentially for the treatment of plaque psoriasis and rheumatic disorders.

Research Code BAX-2200; CHS-0214

CAS No. 185243-69-0 (Etanercept）

Adalimumab biosimilar (Coherus BioSciences)

Phase III Active

A tumor necrosis factor α (TNFα) inhibitor potentially for the treatment of plaque psoriasis.

Research Code CHS-1420

CAS No. 331731-18-1 (Adalimumab)

Gerilimzumab

Phase I Active

An anti-IL-6 antibody potentially for the treatment of rheumatoid arthritis.

Research Code ARGX-109; GB-224; RYI-008

CAS No.

ARGX-110

Phase II Active

A CD70 targeted antibody potentially for the treatment of haematological malignancies, nasopharyngeal cancer and solid tumour.

Research Code ARGX-110

CAS No.

Anti-cMet SIMPLE Antibody

Phase I Active

A c-met inhibitor potentially for the treatment of solid tumours.

Research Code ARGX-111

CAS No.